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1 ABSTRACT  
The ABCB1 gene encodes the P-glycoprotein, an efflux pump for some antineoplastic 
agents which acts as a resistance mechanism to chemotherapy. Three SNPs (C3435T, 
C1236T and G2677T/A), are the most widely studied in ABCB1. The inconsistent 
conclusions about the association of these polymorphisms and the response to 
chemotherapy in breast cancer (BC) patients prompted us to conduct a meta-analysis.  
A total of nine (770 patients), five (566 patients) and three studies (367 patients) 
relating the ABCB1 C3435T, C1236T and G2677T/A polymorphisms respectively, were 
included.  
The main analysis revealed a lack of association between ABCB1 polymorphisms and 
response to chemotherapy in every genetic model: C3435T (dominant OR: 0.888; 
95%CI: 0.558-1.413), C1236T (dominant OR: 1.968; 95%CI: 0.609-6.362) and 
G2677T/A (GG vs GT+GA+TT+TA+AA OR: 0.854; 95%CI: 0.418-1.744). Stratification 
by ethnicity, cancer type and response criteria did not change the pattern of results. 
The available evidence indicates that three polymorphisms within ABCB1; C3435T, 
C1236T and G2677T/A, cannot be considered a reliable predictor of response to 
chemotherapy in BC patients.1 
2 KEYWORDS 
META-ANALYSIS 
ABCB1 
                                                            
1 ABCB1  (ATP‐binding  cassette,  B1),  ACT  (Adjuvant  Chemotherapy),  BC  (Breast  Cancer),  FAC 
(Fluouracil‐Adryamicin‐Cyclophosphamide),  FEC  (Fluouracil‐Epirubicin‐Cyclophosphamide), 
LABC  (Locally  Advance  Breast  Cancer), MBC  (Metastatic  Breast  Cancer),  NACT  (Neoadjuvant 
Chemotherapy), SNP (Single Nucleotide Polymorphism) 
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3 INTRODUCTION 
Breast cancer (BC) is the most common cause of cancer-related death in women in the 
world [1]. In the recent decades, substantial progress has been made in the treatment 
of BC. BC patients are treated neoadjuvantly (prior surgery) or adjuvantly with 
chemotherapy, HER2-targeted drugs (if HER2-positive), hormonal therapy, or a 
combination of these. The chemotherapeutic drugs which are most commonly used 
against BC include anthracyclines (doxorubicin and epirubicin) and taxanes (paclitaxel 
and docetaxel). These can be used in combination with fluorouracil (5-FU), 
cyclophosphamide and/or carboplatin [2]. Chemotherapy with anthracyclines or 
taxanes has shown impressive response rates. Polychemotherapy with anthracycline 
and cyclophosphamide showed better results compared to the cyclophosphamide-
methotrexate-fluorouracil scheme [3]. Patients treated with taxane-based schemes at 
first or second-line have shown high response rates [2]. However, there is a low to 
moderate risk of recurrence [4]. 
Clinical factors including stage, size of the tumour, number of lymph nodes involved, 
hormonal receptors or HER2 status, alter the response to chemotherapy [5]. Other 
mechanisms, such as genetic differences in drug transporters, may contribute to the 
inter-individual variations in treatment outcomes [6]. The ATP-binding cassette, B1 
(ABCB1) gene encodes the P-glycoprotein, an efflux pump for some antineoplastic 
agents (anthracyclines, taxanes or tamoxifen) which acts as a resistance mechanism 
to chemotherapy [7,8]. Three single nucleotide polymorphisms (SNPs); C1236T 
(rs1128503), C3435T (rs1045642) and G2677T/A (rs2032582), are the most widely 
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studied SNPs in ABCB1 [9]. While the ABCB1-2677G>T/A gene polymorphism results 
in an amino-acid change from Ala to Ser/Thr at codon 893, the 1236C>T (Gly412Gly) 
and 3435C>T (Ile1144Ile) SNPs are synonymous [10].  
3.1 ABCB1- C3435T 
The association between the ABCB1-C3435T gene polymorphism and treatment 
outcomes response in BC patients treated with neoadjuvant chemotherapy remains 
controversial. A meta-analysis published in 2012, including 7 studies (464 patients), 
found no influence between the ABCB1-C3435T gene polymorphism and treatment 
response in BC patients [11]. Recent studies have shown an association of the 
ABCB1-C3435T gene polymorphism with treatment response, although they differ in 
the positive effect of the T-allele on the response [12,13]. In 148 BC patients treated 
with neoadjuvant chemotherapy, the ABCB1-C3435T T-allele carriers had a higher 
response (T-allele vs CC: 43.4% vs 23.8%, OR: 2.695; p = 0.02) [12], whereas in 153 
BC patients also treated with neoadjuvant chemotherapy, the C-allele was associated 
with higher response (C-allele vs TT: 71.2 vs 33.3%, p = 0.001) [13]. 
A more recent meta-analysis including 8 studies (608 cases) found no association 
between the treatment response and the dominant model (CT + TT vs CC) of the 
ABCB1-C3435T gene polymorphism (OR: 1.13; 95% CI: 0.58-0.37; p = 0.71) [14]. 
More recently, no association has been found either in a study of Kurdish BC patients 
(100 cases/200 controls) [15] or in 83 BC patients treated with chemotherapy plus 
trastuzumab [16]. 
3.2 ABCB1- C1236T 
T-allele carriers of the ABCB1-C1236T gene polymorphism showed worse response 
(T-allele vs CC: 58.3% vs 85%; OR non-responders/responders: 4.63; p = 0.021) in 100 BC 
patients treated with neoadjuvant chemotherapy [14]. These results were further 
confirmed in other studies (Agarwal: 2015fk, Tulsyan: 2014cy}. However, a meta-
 
 
4
analysis conducted in 2013 by these authors, which included 3 studies (373 patients), 
found no association between the dominant model of the ABCB1-C1236T gene 
polymorphism, but a trend towards response to treatment (OR 1.77, 95% CI: 1.01-3.1; 
p = 0.05) [14]. 
Recent studies not included in this meta-analysis have shown conflicting results. One 
study found an association between TT and CT genotypes and poor response to 
chemotherapy (OR: 0.35; 95 CI%: 0.13-1.90; p= 0.03) [17] in 100 Arabic BC patients 
treated with anthracycline-based chemotherapy. Another study performed in 83 
Caucasian HER2-positive BC patients treated with chemotherapy plus trastuzumab 
showed no association, which was likely due to the smaller sample size [16].  
3.3 ABCB1-2677 G>T/A 
The ABCB1-G2677T/A gene polymorphism was not associated with response to 
chemotherapy in 103 Korean MBC patients treated with adjuvant anthracycline plus 
paclitaxel [18]. This result was confirmed in a another Asian cohort of 153 BC patients 
treated with neoadjuvant anthracycline-based chemotherapy [13] and in an Indian 
study of 111 of BC patients treated with neoadjuvant/adjuvant chemotherapy [19]. 
BC patients (61.5% HER2-positive) with GG + GT + GA genotypes of the ABCB1-
G2677T/A gene polymorphism treated with the fluorouracil-doxorubicin-
cyclophosphamide scheme, showed higher resistance to treatment than TT + TA 
patients. The multivariate analysis showed an OR of 3.19 (95% CI: 0.98 - 10.39; p = 
0.053) [20].  
The inconsistent conclusions in the association of the ABCB1 C1236T, C3435T and 
G2677T/A gene polymorphisms and the response to chemotherapy in BC patients led 
us to conduct a meta-analysis encompassing evidence from all published studies, in 
order to provide a more precise estimation of the association.  
 
 
5
4 Material and methods 
4.1 Study design 
A meta-analysis was carried out. 
4.2 Literature search strategy  
A literature search was carried out using PubMed, Embase, Ovid and Scielo, and 
included all papers published until December 20th 2016, containing the keywords 
“ABCB1”, “polymorphism”, "breast”, “cancer" and “response”. In order to achieve a 
comprehensive literature, we also identified additional studies by screening reference 
lists of key studies or reviews. The literature retrieval was performed in duplication by 
two independent reviewers (AMP and MCG). 
The inclusion criteria used for literature selection were:  
1 Original papers. 
2 Performed in humans. 
3 Studies that explore the association between the three selected SNPS and 
chemotherapy response. 
4 Papers with sufficient data to calculate odds ratio and 95% confidence interval. 
5 Chemotherapy response evaluation by Response Evaluation Criteria In Solid 
Tumors (RECIST)/ World Health Organisation (WHO) criteria.  
6 Papers written in English or Spanish.  
The exclusion criteria were: 
1 Studies reporting overlapping data. 
2 Studies with incomplete data. 
3 Studies with duplicated data 
4.3 Data extraction 
Data was carefully extracted from all eligible studies independently by two investigators 
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according to the aforementioned inclusion criteria. The following information of the 
studies were extracted: first author, published year, country, ethnicity, numbers of 
patients included in the study, genotype frequencies according to chemotherapy 
response, clinical stage, treatment protocols, genotyping methods and response 
evaluation criteria. Two reviewers completed the data extraction and reached 
consensus on all of the extracted data (AMP and MCG). Any discrepancies in the data 
extraction following this were resolved by a third reviewer (ASP) undertaking data 
extraction and analysis.   
4.4 Statistical analysis 
The strength of the association between the ABCB1 C3435T, C1236T and G2677T/A 
gene polymorphisms and the response to BC treatment therapies was measured with 
the ORs and their 95% confidence intervals. First, treatment response was estimated 
with all the available studies for each polymorphism according to the dominant (CT + 
TT vs CC), recessive (TT vs CC + CT) and co-dominant (CT vs CC and TT vs CC) 
models in the case of the ABCB1 C3435T and C1236T gene polymorphisms. Several 
models were used for the ABCB1-G2677T/A gene polymorphism (GG + GT + GA vs 
TT + TA + AA; GG vs GT + GA + TT + TA + AA; GG vs GT + GA; GG vs TT + AA + 
AT; GT + GA vs TT + AA + AT). 
For the meta-analysis, the heterogeneity of the studies was determined using the 
Cochran Q chi-square test (p < 0.05 was considered as significant heterogeneity), 
alongside the degree of inconsistency presented as the I2 index where I2 of 0-25% = no 
heterogeneity; I2 of 25-50% = moderate heterogeneity; I2 of 50-75% = high 
heterogeneity and I2 of 75-100% = extreme heterogeneity. The combined OR of all 
studies was calculated using the DerSimonian-Laird random effects model. The effect 
of the study was considered statistically significant if the confidence interval of the 
combined OR did not contain 1. The data of each analysis were graphically 
represented using funnel plots generated by the STATA program (Stata Software 
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Package version 10 (StataCorp LP, College Station, Texas, USA)). The bias of 
publication was analysed by the Begg`s and Egger`s tests. 
We analysed the overall effect of all studies for each of the ABCB1 gene 
polymorphisms, - C3435T, C1236T and G2677T/A, according to ethnicity, tumor type 
and response criteria. The software used for the meta-analysis was Metadisc [21].  
5 RESULTS 
5.1 Study characteristics 
A total of 44 studies were found with the keywords "ABCB1", "polymorphism", "breast", 
"cancer", "response". 
We excluded 19 studies because they were written in Japanese, they included only 
pharmacokinetic data or because the  analysis was performed in non-BC patients. 
Seventeen studies were selected after eliminating all meta-analyses, one article whose 
drug in study was liposomal doxorubicin, one which considered survival as the 
dependent variable instead of response, and another which assessed only 
modifications in the expression of ABCB1. Of these 17, three further articles were 
discarded. Two had not used the RECIST/WHO criteria as a response measure and 
the third did not have the response data available for later use. Of the remaining 
articles, three had been developed by the same research group. The first,(Tulsyan et 
al. [27]) was excluded because all data had been included in the study by Agarwal et 
al. [19]. This study  [19] was kept for the general analysis as it was the most recently 
published article and included patients with various types of BC. The third article, by 
Chaturvedi et al. [14], had also been published by the same research group. This study 
was used for the subgroup analysis which focused on the type of cancer, as its patients 
had locally advanced breast cancer (LABC) or metastatic breast cancer (MBC). The 
information from the final 12 studies included in analysis was extracted according to 
the gene polymorphism. This resulted in nine articles being included for the ABCB1-
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C3435T gene polymorphism, five for ABCB1-C1236T and three for ABCB1-G2677T/A. 
All characteristics for each of the studies are summarised in tables 1 and 2. 
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Table 1. Characteristics of the studies included in the meta-analysis.  
Reference SNP Cancer type N Age 
NACT/ 
ADJ 
Scheme Etnia 
Genotyping  
Method  
Response  
Criteria 
Kafka et al. 2003 
[22] 
C3435T LABC 68 
Mean 53  
(27-78) 
NACT ANTHRACYCLINE-BASED 
GERMAN  
(CAUCASIAN) 
PCR-SEQ RECIST 
Ashariati et al. 2008 
[23] 
C3435T LABC 19 Median 46.5 NACT NA 
INDONESIAN 
(ASIAN) 
PCR-SEQ RECIST 
Chang et al. 2009 
[18] 
C3435T 
G2677T/A 
MBC 103 Median 49 ACT ANTHRACYCLINE + PACLITAXEL KOREAN (ASIAN) PCR-SEQ RECIST 
George et al. 2009 
[24] 
C3435T LABC 76 Mean 48.7 NACT FAC INDIAN  PCR-RFLP RECIST 
Cizmarikova et al. 
2010 
[25] 
C3435T LABC 38 Mean 55 NACT ANTHRACYCLINE-BASED SLOVAK (CAUCASIAN) PCR-RFLP RECIST 
Zhang et al. 2011 
[26] 
C3435T 
C1236T 
LABC 119 Median 49 NACT ANTHRACYCLINE-BASED CHINESE (ASIAN) PCR-RFLP RECIST 
Ji et al. 2012 
[13] 
C3435T 
C1236T 
G2677T/A 
PRIMARY 153 Median 48 NACT ANTHRACYCLINE-BASED CHINOS (ASIAN) PCR-RFLP WHO 
Alsaif et al. 2013 C1236T DE TODOS 100 Mean 51.5 ACT ANTHRACYCLINE-BASED ARABIC TAQMAN WHO 
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[17] 
Chaturvedi et al. 2013 
[14] 
C3435T 
C1236T 
LABC y MBC 100 NA ACT / NACT FAC/FEC INDIAN PCR-RFLP RECIST 
Agarwal et al. 2015 
[19] 
C3435T 
C1236T 
G2677T/A 
ALL TYPES 111 Mean 48.92 ACT / NACT ANTHRACYCLINE-BASED INDIAN PCR-RFLP RECIST 
Madrid et al. 2016 
[16] 
C3435T 
C1236T 
ALL TYPES 83 
Mean  
(52 ± 13) 
ACT/ NACT ANTHRACYCLINE-BASED 
SPANISH  
(CAUCASIAN) 
TAQMAN RECIST 
ACT (Adjuvant chemotherapy), BC (Breast Cancer), LABC (Locally Advance Breast Cancer), MBC (Metastatic Breast Cancer), FAC (Fluorouracil-adriamycin-cyclophosphamide), FEC 
(Fluorouracil-epirubicin- cyclophosphamide), NA: Not available, NACT (Neoadjuvant Chemotherapy), Seq (Sequencing) 
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Table 2. Genotype distribution of the studies included in the meta-analysis. 
Reference Genotypes C3435T 
Genotypes 
C1236T 
Genotypes 
G2677T/A 
 CC CT TT CC CT TT GG GT or GA 
TT or AA or 
AT 
Kafka et al. 2003 [22] 14 39 15       
Ashariati et al. 2008 [23] 0 5 14       
Chang et al. 2009 [18] 53 10 40    23 44 36 
George et al. 2009 [24] 8 35 23       
Cizmarikova et al. 2010 
[25] 5 25 8       
Zhang et al. 2011 [26] 45 53 21 16 64 41    
Ji et al. 2012 [13] 34 98 21 19 56 78 26 86 41 
Alsaif et al. 2013 [17]    73 11 16    
Chaturvedi et al. 2013 [14] 10 49 41 20 44 36    
Agarwal et al. 2015 [19] 15 50 46 23 48 40 3 54 54 
Madrid et al. 2016  [16] 21 51 11 33 42 8    
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5.2 Meta-analysis 
Nine articles were included for the ABCB1-C3435T gene polymorphism (770 patients) 
to calculate the combined OR (Table 1). There was no association of this 
polymorphism with the response to chemotherapy in patients with BC in any of the 
models (dominant, recessive, codominant) (Table 3). 
Table 3. Response to chemotherapy depending on different ABCB1-C3435T genetic 
models and groups of patients (ethnicity/cancer type). 
Model Total or subgroup of patients N OR (95% CI) I2 (%) P 
Dominant (CT+TT vs CC) Global 8 0.888 (0.558 - 1.413) 21.2 0.261 
 Caucasian 3 1.263 (0.193-8.253) 58.4 0.090 
 Asian 3 0.797 (0.497-1.280) 1.7 0.362 
 Indian 2 1.168 (0.334 - 4.084) 41.2 0.192 
 All types + primary 3 1.217 (0.643 - 2.302) 6.7 0.342 
 LABC + MBC 6 0.961 (0.436- 2.119) 46 0.099 
 RECIST 7 0.807 (0.471 - 1.383) 22.4 0.258 
Recessive (TT vs CT + CC) Global 8 0.993 (0.519 - 1.900) 61.3 0.008 
 Caucasian 3 0.875 (0.316-2.420) 0 0.510 
 Asian 3 0.965 (0.267-3.483) 78.9 0.003 
 Indian 2 0.948 (0.394 - 2.285) 54.1 0.140 
 All types + primary 3 2.007 (0.695 - 5.798) 60.7 0.078 
 LABC + MBC 6 0.830 (0.455 - 1.513) 45.1 0.091 
 RECIST 8 0.812 (0.484 - 1.361) 30.9 0,182 
CT vs CC Global 8 0.834 (0.538 - 1.292) 0 0.467 
 Caucasian 3 1.077 (0.544-2.131) 0 0.760 
 Asian 3 0.709 (0.412-1.220) 75.3 0.017 
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 Indian 2 1.262 (0.468 - 3.404) 0 0.361 
 All types + primary 3 1.008 (0.535 - 1.898) 0 0.466 
 LABC + MBC 6 1.004 (0.426 - 2.368)   38.8 0.147 
 RECIST 7 0.808 (0.467 - 1.397) 8.4 0,364 
TT vs CC Global 8 1.146 (0.511 - 2.571) 57 0.023 
 Caucasian 3 1.244 (0.096-16.124) 65 0.057 
 Asian 3 1.238 (0.366-4.190) 0 0.609 
 Indian 2 1.083 (0.215 - 5.444) 60.3 0.113 
 All types + primary 3 2.327 (0.756 - 7.161) 41.8 0.179 
 LABC + MBC 6 0.830 (0.455 - 1.513) 45.1 0.091 
 RECIST 7 0.848 (0.415 - 1.734) 34.0 0.168 
N: studies, All types (BC of all stages) 
 
Five studies, with a total of 566 patients were selected for analysis of the ABCB1-
C1236T gene polymorphism. No association of this polymorphism with the response to 
chemotherapy was found in patients with BC, in any model (Table 4). 
Table 4. Response to chemotherapy depending on different ABCB1-C1236T genetic 
models and groups of patients (ethnicity/cancer type). 
Model Total or subgroup of patients N OR (95% CI) 
I2 
(%) P 
Dominant (CT+TT vs CC) Global 5 1.968 (0.609 - 6.362) 79.9 0.001 
 Asian 2 0.956 (0.453-2.020) 0 0.640 
 All types 4 2.507 (0.596 - 10.543) 82.5 0.001 
 LABC + MBC 2 1.846 (0.323 - 10.545) 76.3 0.040 
 RECIST 3 1.22 (0.53 – 2.82) 39.6 0.1912 
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 WHO 2 1.029 (0.429 - 2.469) 0 0.5473 
Recessive (TT vs CT + 
CC) Global 5 1.951 (0.690 - 5.519) 82.2 0.000 
 Asian 2 1.045 (0.390 - 2.804) 72.5 0.057 
 All types 4 2.753 (0.814 - 9.307) 80.7 0.001 
 LABC + MBC 2 0.845 (0.446 - 1.601) 20.3 0.263 
 RECIST 3 0.909 (0.531 -1.556) 0 0,399 
 WHO 2 1.376 (0.814 - 2.325) 0 0,480 
CT vs CC Global 5 1.384 (0.576 - 3.323) 55.4 0.062 
 Asian 2 0.867 (0.390 -1.928) 0 0.827 
 All types 4 1.578 (0.498 - 5.001) 64.9 0.036 
 LABC + MBC 2 2.117 (0.399 - 11.233) 72 0.059 
 RECIST 3 1.275 (0.362 - 4.487) 68.1 0.044 
 WHO 2 1.720 (0.278 -10.632) 63.7 0,097 
TT vs CC Global 5 2.472 (0.610 -10.019) 80.5 0.000 
 Asian 2 0.963 (0.408-2.271) 13.1 0.283 
 All types 4 3.660 (0.754 - 17.757) 79.1 0.002 
 LABC + MBC 2 1.498 (0.227 - 9.897) 76.3 0.040 
 RECIST 3 1.246 (0.320 - 4.861) 60 0.082 
 WHO 2 7.106 (0.278 - 181.59) 91.7 0.001 
N: studies, All types (BC of all stages) 
 
After the stratification by ethnicity, type of cancer and the criteria to measure the 
response according to the dominant, recessive or codominant models, no influence of 
these factors was found to be associated with the response to chemotherapy in BC 
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patients for either the ABCB1 C3435T (Table 3, Figures 1 and 2) or C1236T (Table 4, 
Figure 3) gene polymorphisms. 
Figure 1. Forest plot of the dominant model of ABCB1-C3435T gene polymorphism by 
ethnicity. 
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Figure 2. Forest plot of the dominant model of ABCB1-C3435T gene polymorphism by 
cancer type. 
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Figure 3. Forest plot of the dominant model of ABCB1-C1236T gene polymorphism by 
the criteria measurement of the response. 
 
The meta-analysis for ABCB1-G2677T/A which included three studies and 367 
patients, did not reveal an association between the polymorphism and the response to 
chemotherapy (table 4). No association between the ABCB1-G2677T/A gene 
polymorphism and response to chemotherapy was found after stratification by ethnicity 
(two studies in Asian population) or cancer type (two studies of all types of cancer) in 
any model (table 5). 
Table 5. Response to chemotherapy depending on different ABCB1-G2677T/A genetic 
models and groups of patients (ethnicity/cancer type). 
Model Total or subgroup of patients N OR (95% CI) 
I2 
(%) P 
GG + GT + GA vs TT + TA + 
AA Global 3 0.804 (0.506-1.278) 0 0.912 
 Asian 2 0.779 (0.434 – 1.400) 0 0.694 
NOTE: Weights are from random effects analysis
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 All types 2 0.851 (0.500 -1.450) 0 0.986 
GG vs GT + GA + TT + TA + 
AA Global 3 0.854 (0.418-1.744) 3.1 0.356 
 Asian 2 0.934 (0.442 -1.973) 8.3 0.296 
 All types 2 0.602 (0.246 – 1.475) 0 0.444 
GG vs GT + GA Global 3 0.929 (0.374-2.308) 25.6 0.261 
 Asian 2 1.071 (0.406 -2.825) 39.2 0.200 
 All types 2 0.614 (0.243 -1.550) 0 0.453 
GG vs TT + AA + AT Global 3 0.708 (0.321-1.560) 0 0.575 
 Asian 2 0.780 (0.344 -1.769) 0 0.573 
 All types 2 0.557 (0.203 – 1.533) 0 0.456 
GT + GA vs TT + AA + AT Global 3 0.824 (0.511 - 1.330) 0 0.673 
 Asian 2 0.765 (0.414 -1.412) 0 0.422 
 All types 2 0.928 (0.538 – 1.599) 0 0.997 
N: studies, All types (BC of all stages) 
 
5.3 Test for heterogeneity 
The heterogeneity of the studies used in each comparison of the ABCB1 C3435T and 
C1236T gene polymorphisms and response to chemotherapy, were diverse. These are 
detailed in Tables 3, 4 and 5 and include the degree of inconsistent data (I2 index) and 
the Cochran Q chi-square test (heterogeneity: p<0.05). Heterogeneity was higher for 
the ABCB1-C1236T polymorphism models. 
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5.4 Publication bias 
The dominant model of ABCB1-C3435T did not present publication bias, calculated by 
the Begg test (p = 0.293; p continuity corrected = 0.368) and the Egger test results (p = 
0.891). 
Similarly, there was no publication bias in the dominant model of ABCB1-C1236T, 
according to the Begg (p = 0.73; p continuity corrected = 0.462) and the Egger test (p = 
0.470). The graphical representations of these tests are shown below (Figures 4 and 
5). 
Figure 4. Begg’s funnel plot for publication bias test (ABCB1-C3435T dominant model).  
  
Begg's funnel plot with pseudo 95% confidence limits
 lno
r
s.e. of: lnor0 .5 1
-2
0
2
  
 
20
 
Figure 5. Begg’s funnel plot for publication bias test (ABCB1-C1236T dominant model). 
 
The model (GG vs GT + GA + TT + TA + AA) of ABCB1-G2677T/A did not present 
publication bias as showed by the Begg test (p = 0.317; p continuity corrected = 1.0) 
(Figure 6). 
Figure 6. Begg’s funnel plot for publication bias test (ABCB1-G2677T/A GG vs GT + 
GA + TT + TA + AA model). 
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6 DISCUSSION 
Current therapeutic management of patients with HER2 positive BC, including various 
combinations of chemotherapeutic agents, HER2 targeting drugs and hormone 
therapy, has greatly improved the outcomes in these patients. Although these schemes 
often achieve favorable results, response to treatments remains a challenge for 
clinicians. ABCB1 gene polymorphisms have been proposed as potential predictors of 
response to chemotherapy. In the present study, we performed a meta-analysis to 
evaluate the association between the ABCB1 gene polymorphism and response to 
chemotherapy.  
The association of the ABCB1-C3435T polymorphism and response in BC patients 
treated with neoadjuvant chemotherapy was initially suggested in a study of 68 patients 
with locally advanced BC who showed better clinical response in patients carrying the 
TT genotype of ABCB1-C3435T (OR: 4.38, 95% CI: 1.2-16.1, p = 0.029) [22]. In two 
meta-analyses, one published in 2012 which included 464 patients [11] and the second 
published in 2013 which included 608 individuals {Chaturvedi: 2013ch}, the ABCB1-
C3435T gene did not influence the response to treatment. Other studies have 
attempted to refute this lack of association with response to treatment, but have failed 
to find consistency in the effect of the T allele on clinical outcome. In a study of 
Chinese BC patients, those with the ABCB1-C3435T T allele showed an improved 
response to neoadjuvant chemotherapy (43.4% vs 23.8%, OR: 2.695, p = 0.02) [12]. 
Conversely, patients with TT genotype of ABCB1-C3435T showed a poorer response 
to neoadjuvant chemotherapy (33.3 vs. 71.2%, p = 0.001) [13]. 
Our meta-analysis included 770 patients from nine studies confirmed the absence of 
the association between the response to chemotherapy and ABCB1-C3435T. These 
results are in agreement with the meta-analysis by Chen et al. [11] and Chaturvedi et 
al. [14]. The meta-analysis by Chen et al. included seven studies (464 patients), three 
of which included Caucasian populations, three which included Asian populations and 
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one included a mixed ethnic group (Brazilians). All patients had BC in advanced stages 
(6 LABC and 1 MBC), and the sample size of the studies varied between 19-119 
cases. The meta-analysis published by Chaturvedi et al. encompassed 608 patients 
from 8 studies. Each of the included studies, were also assessed in the meta-analysis 
by Chen et al., with the exception of the study by Ji et al. [13], which was conducted in 
an Asian population, and data from their own study, focused on an Indian population 
[14]. 
In our meta-analysis, the stratified analysis by types of cancer (primary + all types vs 
LABC + MBC), also showed no association with the response to chemotherapy in any 
genetic model of the ABCB1-C3435T polymorphism, with a high heterogeneity, 
especially in the subgroup of patients with LABC + MBC (I2 = 46.0%; p = 0.099). 
Other polymorphisms in ABCB1 have been explored as biomarkers of response. The 
T-allele of the ABCB1-C1236T gene polymorphism was associated with a poorer 
response (58.3% vs 85%, OR non-responders/responders: 4.63; p = 0.021) in 100 Indian BC 
patients treated with neoadjuvant chemotherapy, cyclophosphamide plus epirubicin or 
doxorubicin) [15,19]. A similar trend was demonstrated by carriers of the T allele in a 
small cohort of 58 patients treated with neoadjuvant chemotherapy (57.4% vs. 81.8%, 
OR non-responders/responders: 3.33; p = 0.150), but without a statistically significant 
association, which is most likely due to the small sample size [27]. In our meta-
analysis, the ABCB1-C1236T genetic polymorphism did not influence the response. 
The different genetic models (dominant, recessive and co-dominant) of ABCB1-
C1236T were not associated with the response to chemotherapy in the global meta-
analysis. Stratification by ethnicity, cancer type and response measurement criteria did 
not provide information about the possible influence of these variables on the response 
to chemotherapy in BC patients. This data is in line with the meta-analysis including 
373 patients, conducted by an Indian research group, comprising three studies, two in  
Asian population, and their results in Indian population. They did not find an 
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association between the ABCB1-C1236T gene polymorphism and response to 
chemotherapy in patients with BC, although a trend was shown (OR: 1.77; 95% CI: 
1.01-3.10; p = 0.05) [14]. Our meta-analysis included all studies to date with a total of 
five (566 patients), increasing the accuracy of the study, and thus confirming the non-
association of this polymorphism with the response to chemotherapy in BC patients. 
The ABCB1-G2677T/A gene polymorphism was not associated with response to 
chemotherapy in 103 Korean MBC patients treated with adjuvant anthracycline plus 
paclitaxel [18]. This result was confirmed in a another Asian cohort of 153 BC patients 
treated with neoadjuvant anthracycline-based chemotherapy [13] and in an Indian 
study of 111 of BC patients treated with neoadjuvant/adjuvant chemotherapy [19]. Our 
meta-analysis included three studies (two in Asian population and one in an Indian 
population), and did not find an association between the ABCB1-G2677T/A, different 
genetic models and the response to chemotherapy. 
These meta-analyses showed no association between ABCB1 polymorphisms and 
response to chemotherapy, despite some studies having shown contradictory results. 
Possible causes of these differences may be the complexity of the phenomenon and 
gene-gene interactions [28]. Some intracellular alterations, as other unknown ABCB1 
polymorphisms and errors in the posttranslational modification in the protein structure 
of P-glicoprotein, might balance the effect of these polymorphisms. 
In our meta-analysis, one limitation is the high heterogeneity that has been found in the 
different comparisons, especially in relation to the ABCB1-C1236T gene 
polymorphism. This heterogeneity could be due to the fact that the analysis 
encompasses few studies, five in the global analysis, and fewer in the subgroup 
analyses. 
The evidence provided by this work indicates that the ABCB1 C3435T, C1236T and 
G2677T/A gene polymorphisms are not associated with the response to chemotherapy 
in BC patients. No influence of ethnicity, cancer type and response criteria has been 
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found. Subsequent studies focused on other polymorphisms could clarify the 
importance of this gene in the response to chemotherapy. 
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